本帖最后由 老马 于 2012-1-13 21:20 编辑
! S: P6 _, g) @* T: M' _1 u
5 k4 L4 M8 c9 l0 {爱必妥和阿瓦斯丁的比较
2 O9 s8 [- o' I; K, V
& I4 e5 X+ |/ D1 L2 r* t# m- w% y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 o& _6 z7 p5 Z; f& r9 L; I
1 X1 }/ T7 ~( w: D1 V" W* C
- @: j% H* }, z& s4 ^
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 r1 d9 M4 q% ^$ n
==================================================
. S3 V6 p1 `( Z$ S. H# WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% B* J# V. c* l2 _Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* N# B3 ^5 \: ]/ e- R) W [Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
7 S$ x+ s+ b2 k* l4 N: Y! [
|